Bacillus calmette-guerin substrain tokyo 172-1 live antigen
- Generic Name
- Bacillus calmette-guerin substrain tokyo 172-1 live antigen
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 267H8I71ZT
- Background
Bacillus calmette-guerin substrain tokyo 172-1 live antigen is under investigation in clinical trial NCT03091660 (S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer).
S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer
Phase 3
Active, not recruiting
- Conditions
- Stage 0is Bladder Urothelial CarcinomaStage 0 Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma
- Interventions
- Other: Laboratory Biomarker Analysis
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 1000
- Registration Number
- NCT03091660
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇺🇸Marshfield Clinic-Wausau Center, Wausau, Wisconsin, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath